Abstract
There are several well-established mechanisms involved in radiation-induced cell death in mammalian cell systems. The p53-mediated apoptotic pathway is the most widely recognized mechanism (Lowe et al. Nature 362:847–849, 1993), although apoptosis has long been considered a less relevant mechanism of radiation-induced cell death (Steel, Acta Oncol 40:968–975, 2001; Brown and Wouters, Cancer Res 59:1391–1399, 1999; Olive and Durand, Int J Radiat Biol 71:695–707, 1997). We and others have recently focused instead on the emerging links between radiation, apoptosis, and ceramide and showed that ceramide is a sphingolipid-derived second messenger capable of initiating apoptotic cascades in response to various stress stimuli, including radiation.
Ceramide, the backbone of all sphingolipids, is synthesized by a family of ceramide synthases (CerS), each using acyl-CoAs of defined chain length for N-acylation of the sphingoid long-chain base. Six mammalian CerS homologs have been cloned that demonstrated high selectivity towards acyl-CoAs (Lahiri et al. FEBS Lett 581:5289–5294, 2007), and more recently, it was shown that their activity can be modulated by dimer formation (Mesicek et al. Cell Signal 22:1300–1307, 2010; Laviad et al. J Biol Chem 283:5677–5684, 2008).
This de novo ceramide synthesis has been observed in irradiated cells through a pathway normally suppressed by ataxia telangiectasia-mutated (ATM) protein, a key component of the cellular response to DNA double-strand breaks (Liao et al. J Biol Chem 274:17908–17917, 1999). ATM is not the sole factor known to affect apoptotic potential by modulating CerS activity. Recent work has also implicated protein kinase Cα (PKCα) as a potential CerS activator (Truman et al. Cancer Biol Ther 8:54–63, 2009).
In this review, we summarize involvement of CerS in sphingolipid-mediated apoptosis in irradiated human prostate cancer cells and discuss future directions in this field.
The authors have no conflict of interest or financial ties to disclose.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akao Y, Banno Y, Nakagawa Y, Hasegawa N, Kim TJ, Murate T, Igarashi Y, Nozawa Y (2006) High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem Biophys Res Commun 342:1284–1290
Aldridge DR, Arends MJ, Radford IR (1995) Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogenic survival dose–response. Br J Cancer 71:571–577
Algan O, Stobbe CC, Helt AM, Hanks GE, Chapman JD (1996) Radiation inactivation of human prostate cancer cells: the role of apoptosis. Radiat Res 146:267–275
Ameisen JC (2002) On the origin, evolution, and nature of programmed cell death: a timeline of four billion years. Cell Death Differ 9:367–393
Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R (1995) Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82:405–414
Bowen C, Spiegel S, Gelmann EP (1998) Radiation-induced apoptosis mediated by retinoblastoma protein. Cancer Res 58:3275–3281
Brown JM, Wouters BG (1999) Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59:1391–1399
Canman CE, Kastan MB (1995) Induction of apoptosis by tumor suppressor genes and oncogenes [Review]. Semin Cancer Biol 6:17–25
Crook JM, Perry GA, Robertson S, Esche BA (1995) Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology 45:624–631
DeWeese TL, Shipman JM, Dillehay LE, Nelson WG (1998) Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure. J Urol 159:591–598
Dubray B, Breton C, Delic J, Klijanienko J, Maciorowski Z, Vielh P, Fourquet A, Dumont J, Magdelenat H, Cosset JM (1998) In vitro radiation-induced apoptosis and early response to low-dose radiotherapy in non-Hodgkin’s lymphomas. Radiother Oncol 46:185–191
Ellis PA, Smith IE, McCarthy K, Detre S, Salter J, Dowsett M (1997) Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 349:849
Fadeel B, Orrenius S, Zhivotovsky B (1999) Apoptosis in human disease: a new skin for the old ceremony. Biochem Biophys Res Commun 266:699–717
Flowers M, Fabriás G, Delgado A, Casas J, Abad JL, Cabot MC (2012) C6-Ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth. Breast Cancer Res Treat 133:447–458
Garcia-Bermejo ML, Leekow FC, Fujii T, Wang Q, Blumberg PM, Ohba M, Kuroki J, Han K-C, Lee J, Marquez VE et al (2002) Diacylglycerol (DAG)-lactones, a new class of protein kinase C (PKC) agonists, induce apoptosis in LNCaP prostate cancer cells by selective activation of PKCα. J Biol Chem 277:645–655
Garzotto M, White-Jones M, Jiang Y, Ehleiter D, Liao WC, Haimovitz-Friedman A, Fuks Z, Kolesnick R (1998) 12-O-tetradecanoylphorbol-13-acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase. Cancer Res 58:2260–2264
Garzotto M, Haimovitz-Friedman A, Liao WC, White-Jones M, Huryk R, Heston DWW, Cardon-Cardo C, Kolesnick R, Fuks Z (1999) Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res 59:5194–5201
Haimovitz-Friedman A, Kolesnick RN, Fuks Z (1997) Ceramide signaling in apoptosis. Br Med Bull 53:539–553
Hall EJ, Giaccia AJ (2006a) DNA strand breaks and chromosomal aberrations. In: McAllister L, Bierig L, Barrett K (eds) Radiobiology for the radiologist. Lippincott, Williams & Wilkins, Philadelphia, PA, pp 16–29
Hall EJ, Giaccia AJ (2006b) Repair of radiation damage and the dose-rate effect. In: McAllister L, Bierig L, Barrett K (eds) Radiobiology for the radiologist. Lippincott, Williams & Wilkins, Philadelphia, PA, pp 85–105
Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43:1809–1818
Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, Pehamberger H (2000) Chemosensitization of malignant melanoma by BCL2 antisense therapy. Lancet 356:1728–1733
Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics. CA Cancer J Clin 60:277–300
Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 17:16–23
Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71:587–597
Kimura K, Gelmann EP (2000) Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation. J Biol Chem 275:8610–8617
Kimura K, Bowen C, Spiegel S, Gelmann EP (1999) Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Res 59:1606–1614
Kimura K, Markowski M, Edsall LC, Spiegel S, Gelmann EP (2003) Role of ceramide in mediating apoptosis of irradiated LNCaP prostate cancer cells. Cell Death Differ 10:240–248
Kyprianou N, King ED, Bradbury D, Rhee JG (1997) Bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells. Int J Cancer 70:341–348
Lahiri S, Lee H, Mesicek J, Fuks Z, Haimovitz-Friedman A, Kolesnick RN, Futerman AH (2007) Kinetic characterization of mammalian ceramide synthases: determination of K(m) values toward sphinganine. FEBS Lett 581:5289–5294
Laviad EL, Albee L, Pankova-Kholmyansky I, Epstein S, Park H, Merrill AH Jr, Futerman AH (2008) Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem 283:5677–5684
Leith JT (1994) In vitro radiation sensitivity of the LNCaP prostatic tumor cell line. Prostate 24:119–124
Leith JT, Quaranto L, Padfield G, Michelson S, Hercbergs A (1993) Radiobiological studies of PC-3 and DU-145 human prostate cancer cells: X-ray sensitivity in vitro and hypoxic fractions of xenografted tumors in vivo. Int J Radiat Oncol Biol Phys 25:283–287
Li WX, Franklin WA (1998) Radiation- and heat-induced apoptosis in PC-3 prostate cancer cells. Radiat Res 150:190–194
Liao W-C, Haimovitz-Friedman A, Persaud R, McLoughlin M, Ehleiter D, Zhang N, Gatei M, Lavin M, Kolesnick R, Fuks Z (1999) Ataxia Telangiectasia-mutated gene product inhibits DNA damage-induced apoptosis via ceramide synthase. J Biol Chem 274:17908–17917
Lin T, Genestier L, Pinkoski MJ, Castro A, Nicholas S, Mogil R, Paris F, Fuks Z, Schuchman EH, Kolesnick RN et al (2000) Role of acidic sphingomyelinase in Fas/CD95-mediated cell death. J Biol Chem 275:8657–8663
Liu X, Cheng JC, Turner LS, Elojeimy S, Beckham TH, Bielawska A, Keane TE, Hannun YA, Norris JS (2009) Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets 13:1449–1458
Lock RB, Ross WE (1990) Inhibition of p34cdc2 kinase activity by etoposide or irradiation as a mechanism of G2 arrest in Chinese hamster ovary cells. Cancer Res 50:3761–3766
Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes [see comments]. Nature 362:847–849
Mahdy AE, Cheng JC, Li J, Elojeimy S, Meacham WD, Turner LS, Bai A, Gault CR, McPherson AS, Garcia N et al (2009) Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther 17:430–438
Mathias S, Pena LA, Kolesnick RN (1998) Signal transduction of stress via ceramide. Biochem J 335:465–480
Mesicek J, Lee H, Feldman T, Jiang X, Skobeleva A, Berdyshev EV, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2010) Ceramide synthases 2, 5, and 6 confer distinct roles in radiation-induced apoptosis in HeLa cells. Cell Signal 22:1300–1307
Meyn RE, Stephens LC, Hunter NR, Milas L (1995) Apoptosis in murine tumors treated with chemotherapy agents. Anticancer Drugs 6:443–450
Meyn RE, Milas L, Ang KK (2009) The role of apoptosis in radiation oncology. Int J Radiat Biol 85:107–115
Mizutani Y, Kihara A, Igarashi Y (2006) LASS3 (longevity assurance homologue 3) is a mainly testis-specific (dihydro)ceramide synthase with relatively broad substrate specificity. Biochem J 398:531–538
Mullauer L, Gruber P, Sebinger D, Buch J, Wohlfart S, Chott A (2001) Mutations in apoptosis genes: a pathogenetic factor for human disease. Mutat Res 488:211–231
Nava VE, Cuvillier O, Edsall LC, Kimura K, Milstien S, Gelmann EP, Spiegel S (2000) Sphingosine enhances apoptosis of radiation-resistant prostate cancer cells. Cancer Res 60:4468–4474
Norris JS, Bielawska A, Day T, El-Zawahri A, ElOjeimy S, Hannun Y, Holman D, Hyer M, Landon C, Lowe S et al (2006) Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther 13:1045–1051
Olive PL, Durand RE (1997) Apoptosis: an indicator of radiosensitivity in vitro? Int J Radiat Biol 71:695–707
Olson M, Kornbluth S (2001) Mitochondria in apoptosis and human disease. Curr Mol Med 1:91–122
Orrenius S (1995) Apoptosis: molecular mechanisms and implications for human disease. J Intern Med 237:529–536
Pchejetski D, Doumerc N, Golzio M, Naymark M, Teissié J, Kohama T, Waxman J, Malavaud B, Cuvillier O (2008) Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther 7:1836–1845
Pena LA, Fuks Z, Kolesnick R (1997) Stress-induced apoptosis and the sphingomyelin pathway. Biochem Pharmacol 53:615–621
Reed JC (2002) Apoptosis-based therapies. Nat Rev Drug Discov 1:111–121
Royai R, Lange PH, Vessella R (1996) Preclinical models of prostate cancer. Semin Oncol 23:35–40
Saad AF, Meacham WD, Bai A, Anelli V, Elojeimy S, Mahdy AE, Turner LS, Cheng J, Bielawska A, Bielawski J et al (2007) The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther 6:1455–1460
Scardino PT, Wheeler TM (1988) Local control of prostate cancer with radiotherapy: frequency and prognostic significance of positive results of postirradiation prostate biopsy. NCI Monogr 7:95–103
Scarlatti F, Sala G, Ricci C, Maioli C, Milani F, Minella M, Botturi M, Ghidoni R (2007) Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett 253:124–130
Schenck M, Carpinteiro A, Grassmé H, Lang F, Gulbins E (2007a) Ceramide: physiological and pathophysiological aspects. Arch Biochem Biophys 462:171–175
Seelan RS, Qian C, Yokomizo A, Bostwick DG, Smith DI, Liu W (2000) Human acid ceramidase is overexpressed but not mutated in prostate cancer. Genes Chromosomes Cancer 29:137–146
Shiloh Y (2001) ATM (ataxia telangiectasia mutated): expanding roles in the DNA damage response and cellular homeostasis. Biochem Soc Trans 29:661–666
Spiegel S, Foster D, Kolesnick R (1996) Signal transduction through lipid second messengers. Curr Opin Cell Biol 8:159–167
Sridevi P, Alexander H, Laviad EL, Pewzner-Jung Y, Hannink M, Futerman AH, Alexander S (2009) Ceramide synthase 1 is regulated by proteasomal mediated turnover. Biochim Biophys Acta 1793:1218–1227
Steel GG (2001) The case against apoptosis. Acta Oncol 40:968–975
Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF (1978) Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 21:274–281
Symmans WF, Volm MD, Shapiro RL, Perkins AB, Kim AY, Demaria S, Yee HT, McMullen H, Oratz R, Klein P et al (2000) Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 6:4610–4617
Truman JP, Gueven N, Lavin M, Leibel S, Kolesnick R, Fuks Z, Haimovitz-Friedman A (2005) Down-regulation of ATM protein sensitizes human prostate cancer cells to radiation-induced apoptosis. J Biol Chem 280:23262–23272
Truman JP, Rotenberg SA, Kang JH, Lerman G, Fuks Z, Kolesnick R, Marquez VE, Haimovitz-Friedman A (2009) PKCalpha activation downregulates ATM and radio-sensitizes androgen-sensitive human prostate cancer cells in vitro and in vivo. Cancer Biol Ther 8:54–63
Wollin M, FitzGerald TJ, Santucci MA, Menon M, Longcope C, Reale F, Carlson J, Sakakeeny MA, Greenberger JS (1989) Radiosensitivity of human prostate cancer and malignant melanoma cell lines. Radiother Oncol 15:285–293
Wu J (1996) Apoptosis and angiogenesis: two promising tumor markers in breast cancer. Anticancer Res 16:2233–2239
Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41:491–500
Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A (2008) Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J Urol 179:1368–1373 (discussion 1373)
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Wien
About this chapter
Cite this chapter
Hajj, C., Haimovitz-Friedman, A. (2013). Sphingolipids’ Role in Radiotherapy for Prostate Cancer. In: Gulbins, E., Petrache, I. (eds) Sphingolipids in Disease. Handbook of Experimental Pharmacology, vol 216. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1511-4_6
Download citation
DOI: https://doi.org/10.1007/978-3-7091-1511-4_6
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-1510-7
Online ISBN: 978-3-7091-1511-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)